" class="no-js "lang="en-US"> Draper Esprit Leads $17.5 Million Series A in Hypertension Health-tech Firm Aktiia - Medtech Alert
Wednesday, May 22, 2024

Draper Esprit Leads $17.5 Million Series A in Hypertension Health-tech Firm Aktiia

Draper Esprit, a leading venture capital firm investing in and developing high growth technology businesses, today announces that it has led a $17.5m Series A funding round in hypertension health-tech firm Aktiia.

Aktiia’s automated Optical Blood Pressure Monitoring System for 24-7 use at the wrist is the first available on the market, with accelerating sales growth in the United Kingdom, Ireland, Germany, Austria, Switzerland, France and Italy. The additional investment will be used to expand Aktiia’s commercial footprint in the NHS and key healthcare markets across Europe and to build out a team focusing on the healthcare channel. A percentage of the Series A funds will also go towards obtaining FDA clearance to enable expansion to the US market, following Aktiia’s reception of the CE Mark as a Class IIa medical device in Europe, signifying that the device has been assessed to meet high safety, health and environmental protection requirements.

Aktiia’s solution has gained tens of thousands of users across Europe since launching in Spring 2021.

The wearable conveniently and comfortably gathers data throughout the day, providing comprehensive insights to better inform the diagnosis and management of hypertension—which affects approximately 1.28 billion adults worldwide and remains a leading cause of premature death. The data is then visualised in a free companion app, which allows a digital summary to be easily shared with physicians or family members.

Additional Investors participating in the round include 415 Capital, Redalpine Venture Partners, Verve Capital and Silicon Valley-Based Translink Capital.

Mike Kisch, CEO, Aktiia said:

“At Aktiia, we believe the key to improving cardiovascular health is to provide patients and physicians a deeper understanding of their blood pressure pattern. Before Aktiia, it was not possible to do this at scale. We are excited about expanding access to this technology and the positive impact it can have on reducing major adverse cardiovascular events.”

Dr Inga Deakin, principal, Draper Esprit said:

“A key opportunity for healthtech now is to help people with long-term conditions live healthier lives with fewer complications. Technology that enables better management of these conditions reduces mortality, hospital admissions, and ultimately reduces healthcare related costs. With personalised monitoring of their condition, patients and healthcare providers can cooperate to improve outcomes.

“Core to this management are more accessible, accurate ways to measure biomarkers such as blood pressure. This is what we found in Aktiia, who have built a rigorously tested, non-invasive, automated blood pressure monitoring system at the wrist, providing a comprehensive, longitudinal picture of hypertension in patients. Their strong clinical validation, patient engagement, and market traction are extremely impressive and give us every confidence that Aktiia will transform how hypertension is measured and managed globally.”

Aktiia has also announces that it is an official partner of the International Society of Hypertension and the World Heart Foundation. Both its high patient engagement and rigorous clinical validation enable a strong base of trust and credibility with physicians and industry partners.

Professor Melvin Lobo, NHS Professor of Cardiovascular Medicine and Director of St. Bartholomew’s Hospital Blood Pressure Clinic said:

“I believe we are only scratching the surface of the possible applications for the long-term 24/7 blood pressure data that Aktiia is uniquely capable of providing to physicians. This is an indisputable game changer in enabling a better understanding of our patients’ blood pressure patterns and how to treat them on a personalized basis.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more